Connie Lehman, founder and CEO of Clairity, shares how AI-driven insights can improve early detection, personalize screening, and …
In this episode of the SBI podcast, host Dr. Karla Sepulveda welcomes Connie Lehman, MD, PhD to discuss how artificial intelligence is …
AI-powered risk scoring could enable a more personalized approach to breast cancer screening and prevention
Interview with Clairity CEO Dr. Connie Lehman
Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35
The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in women’s health. Clairity …
TIME’s Annual List Recognizes 100 of the World’s Most Influential Leaders in Health.
Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, …
Clairity, developer of the first image-only AI model authorized by the U.S. Food and Drug Administration (FDA) that estimates a woman’s …
Actionable offering helps enable earlier, more personalized breast cancer interventions.
